Methylene Blue

Methylene Blue (methylthioninium chloride) is a synthetic phenothiazine dye first synthesized by Heinrich Caro in 1876. It holds the distinction of being the first fully synthetic drug used in medicine, introduced by Paul Ehrlich for malaria treatment in 1891. Methylene Blue is a redox-active compound that can accept and donate electrons, cycling between its oxidized (blue) and reduced (leucomethylene blue, colorless) forms. This redox cycling capability allows it to function as an alternative electron carrier in the mitochondrial electron transport chain, shuttling electrons from NADH to cytochrome c and bypassing Complex I and Complex III. Methylene Blue has been investigated in diverse research contexts including mitochondrial dysfunction, neuroprotection, photodynamic applications, and methemoglobinemia (for which it is FDA-approved). It is on the WHO List of Essential Medicines.

Methylene Blue has been investigated for its unique redox cycling properties in the mitochondrial electron transport chain. At low concentrations (nanomolar to low micromolar), researchers observed that Methylene Blue accepts electrons from NADH via Complex I and donates them to cytochrome c, effectively acting as an alternative electron carrier that bypasses dysfunctional segments of the ETC. This bypass maintains mitochondrial membrane potential and ATP production even when Complex I or III is impaired. Studies suggest that this electron shuttling also reduces electron leak to oxygen, decreasing superoxide production and oxidative stress. In methemoglobinemia, Methylene Blue is reduced by NADPH-methemoglobin reductase to leucomethylene blue, which then reduces methemoglobin (Fe³⁺) back to functional hemoglobin (Fe²⁺). In neuroprotection research, Methylene Blue has been investigated for its effects on tau aggregation, mitochondrial function in neuronal models, and NO/cGMP pathway modulation. At higher concentrations, Methylene Blue acts as a pro-oxidant and photosensitizer.

Mitochondrial Electron Carrier

Rojas et al. (2012) characterized Methylene Blue as an alternative mitochondrial electron carrier, demonstrating that it bypasses Complex I-III blockade and maintains ATP production in neuronal models with impaired electron transport [1].

Neuroprotection Research

Oz et al. (2009) reviewed Methylene Blue’s neuroprotective properties across multiple preclinical models, including its effects on mitochondrial function, oxidative stress, and protein aggregation pathways [2].

Historical and Clinical Significance

Schirmer et al. (2011) reviewed Methylene Blue’s history from its synthesis in 1876 to modern applications, describing its FDA-approved use for methemoglobinemia and ongoing research applications [3].